

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

> Tredegar Corporation Consolidated Balance Sheets
> (In Thousands)
> (Unaudited)

| June 30, | Dec. 31, |
| :---: | :---: |
| 1999 | 1998 |

Assets
Current assets:

| Cash and cash equivalents | $\$ 19,867$ | $\$ 25,409$ |
| :--- | ---: | ---: |
| Accounts and notes receivable | 109,696 | 94,341 |
| Inventories | 46,090 | 34,276 |
| Income taxes recoverable | 1,219 | - |
| Deferred income taxes | 8,777 | 8,762 |
| Prepaid expenses and other | 1,782 | 3,536 |
| Total current assets |  | .$----\ldots$ |


| Property, plant and equipment, at cost | 452,247 | 356,411 |
| :---: | :---: | :---: |
| Less accumulated depreciation and amortization | 211,803 | 200, 380 |
| Net property, plant and equipment | 240,444 | 156,031 |
| Venture capital investments | 85,154 | 60,024 |
| Other assets and deferred charges | 39,612 | 41, 886 |
| Goodwill and other intangibles | 153,068 | 32,913 |
| Total assets | \$ 705,709 | \$ 457,178 |
| Liabilities and Shareholders' Equity |  |  |
| Current liabilities: |  |  |
| Accounts payable | \$ 56,802 | \$ 47,551 |
| Accrued expenses | 45,798 | 41, 071 |
| Income taxes payable | - | 243 |
| Total current liabilities | 102,600 | 88,865 |
| Long-term debt | 234,000 | 25,000 |
| Deferred income taxes | 24,708 | 24,914 |
| Other noncurrent liabilities | 8,186 | 8,104 |
| Total liabilities | 369,494 | 146,883 |
| Shareholders' equity: |  |  |
| Common stock, no par value | 98,290 | 95,893 |
| Common stock held in trust for savings restoration plan | $(1,212)$ | $(1,212)$ |
| Unrealized gain on available-for-sale securitie | es 1,405 | 1,376 |
| Foreign currency translation adjustment | $(1,573)$ | $(2,519)$ |
| Retained earnings | 239,305 | 216,757 |
| Total shareholders' equity | 336,215 | 310,295 |
| Total liabilities and shareholders' equity | \$ 705,709 | \$ 457,178 |


|  | Second Quarter Ended June 30 |  | Six Months <br> Ended June 30 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 1999 | 1998 | 1999 | 1998 |
| Revenues: |  |  |  |  |
| Net sales | \$ 194,840 | \$ 169,946 | \$ 374,381 | \$ 326,606 |
| Other income (expense), net | $(1,277)$ | 1,911 | $(1,018)$ | 3,301 |
| Total | 193,563 | 171,857 | 373,363 | 329,907 |
| Costs and expenses: |  |  |  |  |
| Cost of goods sold | 153,986 | 134,449 | 294, 225 | 257,537 |
| Selling, general and administrative | 11,149 | 10,136 | 22,522 | 18,976 |
| Research and development | 5,753 | 3,600 | 9,850 | 6,947 |
| Amortization of intangibles | 782 | 26 | 869 | 34 |
| Interest | 1,517 | 292 | 1,806 | 686 |
| Unusual items | 4,628 | - | 4,628 | (765) |
| Total | 177,815 | 148,503 | 333,900 | 283,415 |
| Income before income taxes | 15,748 | 23,354 | 39,463 | 46,492 |
| Income taxes | 5,558 | 8,193 | 13,975 | 14,035 |
| Net income | \$ 10, 190 | \$ 15,161 | \$ 25,488 | \$ 32, 457 |
| Earnings per share: |  |  |  |  |
| Basic | \$ . 28 | \$ . 42 | \$ . 69 | \$ . 90 |
| Diluted | . 26 | . 39 | . 65 | . 84 |
| Shares used to compute earnings per share: |  |  |  |  |
| Basic | 36,852 | 35,904 | 36,789 | 36,150 |
| Diluted | 38,798 | 38,557 | 38,770 | 38,788 |
| Dividends per share | \$ . 04 | \$ . 04 | \$ . 08 | \$ . 07 |


|  | Six Months Ended Ended June 30 |  |
| :---: | :---: | :---: |
|  | 1999 | 1998 |
| Cash flows from operating activities: |  |  |
| Net income | \$ 25,488 | \$ 32,457 |
| Adjustments for noncash items: |  |  |
| Depreciation | 12,544 | 10,385 |
| Amortization of intangibles | 869 | 34 |
| Write-off of in-process R\&D acquired | 3,458 | - |
| Deferred income taxes | $(1,492)$ | 588 |
| Accrued pension income and postretirement benefits | $(1,837)$ | $(1,773)$ |
| Loss (gain) on sale of venture capital investments | 1,183 | $(2,185)$ |
| Loss (gain) on equipment writedowns and divestitures | 1,170 | (765) |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |
| Accounts and notes receivable | (1, 088 ) | $(4,110)$ |
| Inventories | 4,350 | $(4,015)$ |
| Income taxes recoverable | $(1,219)$ | (777) |
| Prepaid expenses and other | 1,923 | 970 |
| Accounts payable | 5,596 | 6,994 |
| Accrued expenses and income taxes payable | 2,907 | $(4,185)$ |
| Other, net | $(1,482)$ | $(1,575)$ |
| Net cash provided by operating activities | 52,370 | 32,043 |
| Cash flows from investing activities: |  |  |
| Capital expenditures | $(23,182)$ | $(13,604)$ |
| Acquisitions (net of cash acquired of \$1,097 in |  |  |
| 1998; excludes equity issued of \$11,219 in 1998) | $(213,665)$ | $(60,527)$ |
| Venture capital investments | $(31,837)$ | $(13,726)$ |
| Proceeds from the sale of venture capital investments | 2,189 | 2,919 |
| Proceeds from property disposals and divestitures | 252 | 690 |
| Other, net | (126) | (855) |
| Net cash used in investing activities | $(266,369)$ | $(85,103)$ |
| Cash flows from financing activities: |  |  |
| Dividends paid | $(2,940)$ | $(2,508)$ |
| Net increase (decrease) in borrowings | 209,000 | $(5,000)$ |
| Repurchases of Tredegar common stock | - | $(34,163)$ |
| Tredegar common stock purchased by trust for |  |  |
| savings restoration plan | - | (192) |
| Proceeds from exercise of stock options (including related income tax benefits realized) | 2,397 | 1,431 |
| Net cash provided by (used in) financing activities | 208,457 | $(40,432)$ |
| Increase (decrease) in cash and cash equivalents | $(5,542)$ | $(93,492)$ |
| Cash and cash equivalents at beginning of period | 25,409 | 120, 065 |
| Cash and cash equivalents at end of period | \$ 19, 867 | \$ 26,573 |

1. In the opinion of management, the accompanying consolidated financial statements of Tredegar Corporation and Subsidiaries ("Tredegar") contain all adjustments necessary to present fairly, in all material respects, Tredegar's consolidated financial position as of June 30, 1999, and the consolidated results of operations and cash flows for the six months ended June 30, 1999 and 1998. All such adjustments are deemed to be of a normal recurring nature. These financial statements should be read in conjunction with the consolidated financial statements and related notes included in Tredegar's Annual Report on Form 10-K for the year ended December 31, 1998. The results of operations for the six months ended June 30, 1999, are not necessarily indicative of the results to be expected for the full year.
2. On May 17, 1999, Tredegar acquired the assets of Exxon Chemical Company's plastic films business ("Exxon Films") for cash consideration of approximately $\$ 203.9$ million (including estimated transaction costs of $\$ 3.9$ million). The acquisition was funded with borrowings under our revolving credit facility. During the 12 months ended March 31, 1999, Exxon Films had pro forma revenues of $\$ 111$ million and generated pro forma EBITDA (earnings before interest, taxes, depreciation and amortization and excluding potential synergies) of $\$ 24.6$ million. The asset-purchase structure, unlike a stock-purchase transaction, allows Tredegar to deduct for tax purposes over time the full value of depreciable fixed assets and intangibles (goodwill).

Tredegar expects that, by 2001, the annual ongoing benefits from synergies (cost reductions, efficiencies and technology enhancements expected from the integration of Exxon Films into existing operations) will range from \$7-\$9 million.

In addition to Exxon Films, Tredegar acquired:
o The assets of Therics, Inc. ("Therics") on April 8, 1999
o The stock of Canadian-based Exal Aluminum Inc. ("Exal") on The stock of
June 11, 1998
o Two Canadian-based aluminum extrusion and fabrication plants from Reynolds Metals Company ("Reynolds") on February 6, 1998

The assets of Therics were acquired for cash consideration of $\$ 13.6$ million (including transaction costs). Before the acquisition, Tredegar owned approximately $19 \%$ of Therics. Upon the final liquidation of the former Therics, Tredegar will have paid approximately \$10.2 million to effectively acquire the remaining 81\% ownership interest. Therics is developing a new microfabrication technology that has potential applications in drug delivery and a variety of other medical markets. The company's primary focus is on commercializing its TheriForm(TM) technology, a novel process for manufacturing tablets, capsules and implantables with drug release profiles that are expected to provide therapeutic advantages over currently available products. Therics employs 43 people and is part of our Technology Group, which already includes Molecumetics, our drug discovery subsidiary, and Tredegar Investments, our venture capital subsidiary. We recognized a nonrecurring charge of $\$ 3.5$ million (classified in unusual items in the consolidated statements of income) in the second quarter of 1999 related to the write-off of acquired in-process research and development. The amount of the charge was determined through an independent, third-party analysis.

Exal was acquired for $\$ 44.1$ million (including transaction costs), which was comprised of:
o Cash consideration of $\$ 32.9$ million ( $\$ 31.8$ million net of cash acquired)
o
380,172 shares of Class I non-voting preferred shares of
Tredegar's Bon L Canada subsidiary (the "Class I Shares")
The Class I Shares are exchangeable into shares of Tredegar common stock on a one-for-one basis. Each Class I Share is economically equivalent to one share of Tredegar common stock and accordingly accounted for in the same manner. Tredegar funded the cash portion of the purchase price with available cash on hand. Exal operates aluminum extrusion plants in Pickering, Ontario and Aurora, Ontario. Both facilities manufacture extrusions for distribution, transportation, electrical, machinery and equipment, and building and construction markets. The Pickering facility also produces aluminum logs and billet for internal use and for sale to customers.

The former Reynolds plants in Canada were acquired for cash consideration of $\$ 29.1$ million (including transaction costs) using available cash on hand. The plants are located in Ste-Therese, Quebec, and Richmond Hill, Ontario. Both facilities manufacture extruded and fabricated aluminum products used primarily in building and construction, transportation, electrical, machinery and equipment, and consumer durables markets.

Each acquisition was accounted for using the purchase method, and related operating results have been included in Tredegar's consolidated statements of income since the dates acquired. Detailed pro forma financial information for these acquisitions through March 31, 1999, were included in our Form 8-K/A filed on June 25, 1999. Selected historical and pro forma financial information for Tredegar through June 30, 1999, is as follows:

## Tredegar Corporation

Selected Historical and Pro Forma Financial Information (In Thousands Except Per-Share Amounts)

|  | Second Quarter Ended June 30 |  |  | Six Months Ended June 30 |  | Last 12 Months |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1999 | 1998 | 1999 | 1998 | 6/30/99 |
| Net sales |  | 194,840 | \$ 169,946 | \$ 374,381 | \$ 326,606 | \$ 747, 571 |
| Net income: |  |  |  |  |  |  |
| Manufacturing operations |  | \$ 15,997 | \$ 15, 112 | \$ 32,092 | \$ 29,800 | \$ 66,229 |
| Technology: |  |  |  |  |  |  |
| Operating companies |  | $(1,593)$ | (622) | $(2,140)$ | $(1,212)$ | $(3,444)$ |
| Venture capital investments |  | $(1,252)$ | 671 | $(1,502)$ | 1,103 | $(2,211)$ |
| Unusual items |  | $(2,962)$ | - | $(2,962)$ | 2,766 | $(3,387)$ |
| Discontinued operations |  | - | - | - | - | 4,713 |
| Total |  | \$ 10,190 | \$ 15,161 | \$ 25,488 | \$ 32,457 | \$ 61,900 |
| Diluted earnings per share: |  |  |  |  |  |  |
| Manufacturing operations |  | \$ . 41 | \$ . 39 | \$ . 83 | \$ . 77 | \$ 1.71 |
| Technology: |  |  |  |  |  |  |
| Operating companies |  | (.04) | (.02) | (.06) | (.03) | (.09) |
| Venture capital investments |  | (.03) | . 02 | (.04) | . 03 | (.06) |
| Unusual items |  | (.08) | - | (.08) | . 07 | (.09) |
| Discontinued operations |  | - | - | - | - | . 12 |
| Total |  | \$ . 26 | \$ . 39 | \$ . 65 | \$ . 84 | \$ 1.59 |
| EBITDA |  | \$ 31,158 | \$ 27,526 | \$ 61,063 | \$ 53,366 | \$ 123,674 |
| As a \% of net sales |  | 16.0\% | 16.2\% | 16.3\% | 16.3\% | 16.5\% |
| Consolidated pro forma information for acquisitions as if they had |  |  |  |  |  |  |
| occurred at the beginning of 1998: |  |  |  |  |  |  |
| Net sales |  | 208,580 | \$ 212,937 | \$ 417,676 | \$ 422,796 | \$ 846,511 |
| EBITDA |  | 32,945 | 32,259 | 68,745 | 62,191 | 139,472 |
| As a \% of pro forma net sales |  | 15.8\% | 15.1\% | 16.5\% | 14.7\% | 16.5\% |
| Manufacturing operations: |  |  |  |  |  |  |
| Net income |  | 15,331 | 14,850 | 32,274 | 28,404 | 66,069 |
| Diluted earnings per share |  | . 40 | . 39 | . 83 | . 73 | 1.71 |
| Technology operating companies: |  |  |  |  |  |  |
| Net income |  | $(1,712)$ | $(2,168)$ | $(3,647)$ | $(4,148)$ | $(8,116)$ |
| Diluted earnings per share |  | (.04) | (.06) | (.09) | (.11) | (.21) |

Pro forma results assume that Tredegar made the acquisitions at the beginning of 1998. Excluded from the pro forma results are synergies expected from the integration of acquired and existing operations. Accordingly, the pro forma financial information does not purport to be indicative of the future results or the financial position of Tredegar or the net income and financial position that would actually have been attained had the pro forma transactions occurred on the dates or for the periods indicated.

Unusual items in 1999 include the in-process R\&D write-off related to the Therics acquisition (\$2.2 million after deferred income tax benefits) and the write-off of equipment related to excess packaging film capacity (\$749,000 after income tax benefits).
3. The carrying value of venture capital investments was $\$ 85.2$ million ( $\$ 86.2$ million cost basis) at June 30, 1999, and $\$ 60$ million ( $\$ 60.6$ million cost basis) at December 31, 1998. The excess of the cost basis over the carrying value is related to the writedown of certain investments, partially offset by available-for-sale securities stated at their closing market price, with unrealized holding gains excluded from earnings and reported net of deferred income taxes in shareholders' equity until realized. The estimated fair value of venture capital investments was $\$ 98.4$ million at June 30, 1999, and $\$ 70.8$ million at December 31, 1998. The venture capital portfolio is comprised of investments in private venture capital fund limited partnerships and early-stage technology companies with an overall weighted average age of 1.6 years. Most liquidation opportunities are not expected for several years and will depend on many factors, including market conditions.
4. Comprehensive income, defined as net income and other comprehensive income, was \$11.1 million for the second quarter of 1999 and \$17.8 million for the second quarter of 1998. Comprehensive income was $\$ 26.5$ million for the first six months of 1999 and $\$ 33.8$ million for the first six months of 1998. Other comprehensive income includes changes in unrealized gains and losses on available-for-sale securities and foreign currency translation adjustments recorded net of deferred income taxes directly in shareholders' equity.
5. The components of inventories are as follows:

| (In Thousands) |  |
| :---: | :---: |
| June 30 | Dec. 31 |
| 1999 | 1998 |
| \$8,721 | \$4,805 |
| 3,859 | 3,751 |
| 24,137 | 17,690 |
| 9,373 | 8,030 |
| \$46, 090 | \$34,276 |

6. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding. Diluted earnings per share is computed by dividing net income by the weighted average common and potentially dilutive common equivalent shares outstanding, determined as follows:

|  | Second Ended | $\begin{aligned} & \text { (In } \mathrm{T} \\ & \text { arter } \\ & \text { 1e } 30 \end{aligned}$ | ands) <br> Six <br> Ende | $\begin{aligned} & \text { his } \\ & \text { he } 30 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: |
|  | 1999 | 1998 | 1999 | 1998 |
| Weighted average shares outstanding used to compute basic earnings per share | 36,852 | 35,904 | 36,789 | 36,150 |
| Incremental shares issuable upon the assumed exercise of stock options | 1,946 | 2,653 | 1,981 | 2,638 |
| Shares used to compute diluted earnings per share | 38,798 | 38,557 | 38,770 | 38,788 |

Incremental shares issuable upon the assumed exercise of outstanding stock options are computed using the average market price during the related period.
7. The Financial Accounting Standards Board has issued a new standard affecting the accounting for derivative instruments and hedging activities. This standard is not expected to significantly change our operating results, financial condition or disclosures. The new standard will be adopted in the first quarter of 2001.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

## Results of Operations

Second Quarter 1999 Compared with Second Quarter 1998
Financial results for the quarter and year-to-date are summarized on page 7.
The improved quarterly earnings from manufacturing operations were driven by the company's aluminum extrusion business, where profits were up $14 \%$ due to higher volume and the acquisition of Exal Aluminum in June of last year. Profits from Tredegar's ongoing plastic films operations were up $6 \%$ due to the acquisition of Exxon Films (see Note 2 on page 5). Excluding the acquisition, films profits declined. The films business continues to be adversely affected by several factors including higher product development costs, delays in new product introductions, start-up expenses at a new plant in Hungary, and weakness in foreign operations.

Higher losses from technology operations were due to the inclusion of results from Therics, which was acquired on April 8 of this year (see Note 2 on page 5). Losses at Molecumetics, Tredegar's drug discovery subsidiary, were lower versus last year due to higher research collaboration revenues. Second-quarter results include an after-tax loss of $\$ 1.2$ million related to venture capital investment activities, compared to an after-tax gain of $\$ 671,000$ in the same period of last year.

Second-quarter 1999 net sales increased due to acquisitions. On a pro forma basis, net sales declined by $2 \%$ due to lower volume in Film Products and lower selling prices, partially offset by higher volume in Aluminum Extrusions. Lower selling prices reflect a decline in average plastic resin and aluminum ingot costs.

The consolidated gross profit margin during the second quarter of 1999 increased slightly to 21\% from 20.9\% in 1998.

Selling, general and administrative (SG\&A) expenses in the second quarter of 1999 were $\$ 11.1$ million, up from $\$ 10.1$ million in 1998 due primarily to acquisitions and higher spending on new products in Film Products. As a percentage of sales, SG\&A expenses decreased to $5.7 \%$ in 1999 compared with $6 \%$ in 1998.

Research and development expenses increased by $\$ 2.2$ million or $60 \%$ due to the acquisition of Therics and higher spending at Molecumetics.

Interest income, which is included in "Other income (expense), net" in the consolidated statements of income, decreased in the second quarter of 1999 by $\$ 372,000$ due to a lower average cash equivalents balance (see Liquidity and Capital Resources on page 15) and lower yields. The average tax-equivalent yield earned was approximately $4.8 \%$ in 1999 and $5.7 \%$ in 1998 . Interest expense increased by $\$ 1.2$ million due to funds borrowed on a floating-rate basis under our revolving credit facility to acquire Exxon Films. Average debt outstanding during the second quarter was $\$ 128.9$ million (including average floating-rate debt outstanding of $\$ 104.7$ million), up from $\$ 29.2$ million (all $7.2 \%$ fixed-rate
debt) in the second quarter of last year. The average interest rate on debt declined to $5.6 \%$ during the second quarter of 1999 from $7.2 \%$ in 1998 due to a higher proportion of floating-rate debt. The average interest rate on floating-rate debt in the second quarter of 1999 was $5.2 \%$ (the rate as of August 10, 1999, was 5.5\%). For more information, see Liquidity and Capital Resources on page 15.

The effective tax rate excluding unusual items increased to $35.5 \%$ in the second quarter of 1999 from $35.1 \%$ in the second quarter of 1998 due to lower tax exempt income.

Six Months 1999 Compared with Six Months 1998
The improved earnings from manufacturing operations during the first six months were driven by higher volume and acquisitions in our aluminum extrusions business. Profits from ongoing plastic film operations were down due to the adverse effect of several factors including higher product development costs, delays in new product introductions, start-up expenses at a new plant in Hungary, and weakness in foreign operations. The acquisition of Exxon Films on May 17, 1999 (see Note 2 on page 5), had a positive impact on financial results.

Higher losses from technology operations were due to the acquisition of Therics (see Note 2 on page 5). Year-to-date results include an after-tax loss of $\$ 1.5$ million related to venture capital investment activities, compared to an after-tax gain of $\$ 1.1$ million last year.

Net sales for the first six months of 1999 increased due to acquisitions. On a pro forma basis, net sales declined by $1 \%$ due to lower volume in Film Products and lower selling prices, partially offset by higher volume in Aluminum Extrusions. Lower selling prices reflect a decline in average plastic resin and aluminum ingot costs.

The consolidated gross profit margin for the first six months of 1999 increased to $21.4 \%$ from $21.1 \%$ in 1998.

Selling, general and administrative (SG\&A) expenses were $\$ 22.5$ million in 1999, up from $\$ 19$ million in 1998 due primarily to acquisitions and higher spending on new products in Film Products. As a percentage of sales, SG\&A expenses increased to $6 \%$ in 1999 compared with $5.8 \%$ in 1998.

Research and development expenses increased by $\$ 2.9$ million or $42 \%$ due to the acquisition of Therics and higher spending at Molecumetics.

Interest income, which is included in "Other income (expense), net" in the consolidated statements of income, decreased by $\$ 1.2$ million due to a lower average cash equivalents balance (see Liquidity and Capital Resources on page 15) and lower yields. The average tax-equivalent yield earned was approximately $4.9 \%$ in 1999 and $5.7 \%$ in 1998. Interest expense increased by $\$ 1.1$ million due to funds borrowed on a floating-rate basis under our revolving credit facility to acquire Exxon Films. Average debt outstanding during the first six months of 1999 was $\$ 77.3$ million (including average floating-rate debt outstanding of $\$ 52.7$ million), up from $\$ 29.6$ million (all $7.2 \%$ fixed-rate debt) last year. The average interest rate on debt declined to $5.8 \%$ in 1999 from $7.2 \%$ in 1998 due to a higher proportion of floating-rate debt. The average interest rate on floating-rate debt in 1999 was $5.2 \%$ (the rate as of August 10, 1999, was 5.5\%). For more information, see Liquidity and Capital Resources on page 15.

The effective tax rate excluding unusual items increased to $35.5 \%$ in the first six months of 1999 from $35.1 \%$ in 1998 due to lower tax exempt income.

Segment Results

The following tables present Tredegar's net sales and operating profit by segment for the second quarter and six months ended June 30, 1999 and 1998.

Net Sales by Segment
(In Thousands)
(Unaudited)

| Second Ended | Quarter <br> June 30 | Six Months Ended June 30 |  |
| :---: | :---: | :---: | :---: |
| 1999 | 1998 | 1999 | 1998 |
| \$ 75, 267 | \$ 70,711 | \$ 143, 019 | \$ 145,507 |
| 2,218 | 2,992 | 4,478 | 5,605 |
| 115,435 | 95,076 | 223,119 | 172,798 |
| 1,920 | 1,167 | 3,765 | 2,667 |
| - | - | - | 29 |
| \$ 194, 840 | \$ 169,946 | \$ 374,381 | \$ 326,606 |

Operating Profit by Segment
(In Thousands)

Film Products
Fiberlux
Aluminum Extrusions Technology:

Molecumetics Other

Total net sales
(Unaudited)

| Second | Quarter | Six Months |  |
| :---: | :---: | :---: | :---: |
| Ended | June 30 | Ende | 30 |
| 1999 | 1998 | 1999 | 1998 |

Film Products:
Ongoing operations
Unusual items
Total Film Products
Fiberlux
Aluminum Extrusions
Technology:
Molecumetics
Therics
Venture capital investments
Other
Unusual items
Total technology
Total operating profit
Interest income

| $\begin{array}{cc} \$ & 12,344 \\ (1,170) \end{array}$ | \$ 11, 656 | $\begin{gathered} \$ 25,548 \\ (1,170) \end{gathered}$ | \$ 26,590 |
| :---: | :---: | :---: | :---: |
| 11,174 | 11,656 | 24,378 | 26,590 |
| (53) | 359 | (141) | 542 |
| 14,634 | 12,808 | 28,480 | 21,593 |
| (893) | (971) | $(1,747)$ | $(1,465)$ |
| $(1,597)$ | - | $(1,597)$ | - |
| $(1,956)$ | 1,046 | $(2,347)$ | 1,722 |
| - | - | - | (428) |
| $(3,458)$ | - | $(3,458)$ | 765 |
| $(7,904)$ | 75 | $(9,149)$ | 594 |
| 17,851 | 24,898 | 43,568 | 49,319 |
| 257 | 629 | 582 | 1,744 |
| 1,517 | 292 | 1,806 | 686 |
| 843 | 1,881 | 2,881 | 3,885 |
| 15,748 | 23,354 | 39,463 | 46,492 |
| 5,558 | 8,193 | 13,975 | 14,035 |
| \$ 10,190 | \$ 15,161 | \$ 25,488 | \$ 32,457 |

Selected historical and pro forma results for Film Products are summarized below (pro forma results assume that the acquisition of Exxon Films (see Note 2 on page 5) occurred at the beginning of 1998):
Film Products
Selected Historical and Pro Forma Financial Information
(In Thousands)

| Second Quarter |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | \$ 75, 267 | \$ 70, 711 | \$ 89,005 | \$ 96,583 |
| Operating profit | 12,344 | 11,656 | 13,014 | 13,894 |
| First Six Months |  |  |  |  |
| Net sales | 143, 019 | 145,507 | 186,288 | 195,882 |
| Operating profit | 25,548 | 26,590 | 30,890 | 30,572 |

Sales and operating profit in Film Products were higher in the second quarter of 1999 due to the acquisition of Exxon Films. Average selling prices declined due to lower average resin costs. Excluding the acquisition, sales volume and operating profit were down due to the adverse effects of:

| o | Higher product development spending |
| :--- | :--- |
| 0 | Delays in new product introductions |
| 0 | Start-up costs related to a new plant in Hungary |
| 0 | Weakness in foreign operations |

Selected historical and pro forma results for Aluminum Extrusions are summarized below (pro forma results assume that acquisitions in 1998 in this segment (see Note 2 on page 5) occurred at the beginning of 1998):

Aluminum Extrusions
Selected Historical and Pro Forma Financial Information (In Thousands)

| Historical |  | Pro Forma |  |
| :---: | :---: | :---: | :---: |
| 1999 | 1998 | 1999 | 1998 |

Second Quarter

| Net sales | \$ 115,435 | $\$ 95,076$ | $\$ 115,435$ | $\$ 112,202$ |
| :--- | ---: | ---: | ---: | ---: |
| Operating profit | 14,634 | 12,808 | 14,634 | 13,904 |
|  |  |  |  |  |
| First Six Months |  |  |  |  |
| $-------------172,798$ | 223,119 | 218,597 |  |  |
| Net sales | 223,119 | 172,123 |  |  |

Sales and operating profit in Aluminum Extrusions increased in 1999 due to acquisitions, strong demand for architectural and commercial extrusions and a high percentage of mill finish product which maximized the utilization of press capacity. Operating results were adversely affected by press and furnace repairs and resulting downtime at the El Campo, Texas facility, and expenses and disruption associated with the second phase of the press modernization project at the Newnan, Georgia plant.

Molecumetics operating losses decreased for the quarter due to higher research collaboration revenues and increased for the year due to higher costs to support related programs. See Note 2 on page 5 regarding our recent acquisition of Therics.

Losses in the second quarter of 1999 from venture capital investment activities of $\$ 2$ million were comprised of operating expenses of $\$ 605,000$ and investment writedowns of \$1.4 million. Losses in the first six months of 1999 from venture capital investment activities of $\$ 2.4$ million were comprised of operating expenses of $\$ 1.2$ million and net investment losses of $\$ 1.2$ million. The venture capital portfolio is comprised of investments in private venture capital fund limited partnerships and early-stage technology companies with an overall weighted average age of 1.6 years. Most liquidation opportunities are not expected for several years and will depend on many factors, including market conditions.

Tredegar's total assets increased to $\$ 705.8$ million at June 30, 1999, from $\$ 457.2$ million at December 31, 1998, due to the acquisition of Exxon Films and higher fixed assets from capital expenditures in excess of depreciation. Total liabilities increased to $\$ 369.5$ million at June 30, 1999, from $\$ 146.9$ million at December 31, 1998, due mainly to borrowings related to the acquisition of Exxon Films.

Net cash provided by operating activities in excess of capital expenditures and dividends increased to $\$ 26.2$ million in the first six months of 1999 from $\$ 15.9$ million in 1998 due to favorable changes in working capital, partially offset by higher capital expenditures. Higher capital expenditures in Film Products are related to the new facility near Budapest, Hungary, and machinery and equipment purchased for the manufacture of new products (breathable and elastomeric films that are partially replacing conventional diaper backsheet and other diaper components in order to improve comfort and fit). The Hungarian facility, which should be operational during 1999, will produce disposable films for hygiene products marketed in Eastern Europe. Higher capital expenditures in Aluminum Extrusions relate to the second phase of a modernization program at the plant in Newnan, Georgia (the first phase was completed in 1996).

The reasons for the decrease in cash and cash equivalents to \$19.9 million at June 30, 1999, from $\$ 25.4$ million at December 31, 1998, are summarized below:

|  | (In Thousands) <br> Six Months Ended June 30 |  |
| :---: | :---: | :---: |
|  |  |  |
|  | 1999 | 1998 |
| Cash and cash equivalents, beginning of period | \$ 25,409 | \$ 120, 065 |
| Cash provided by operating activities in excess of capital expenditures and dividends | 26,248 | 15,931 |
| Proceeds from the exercise of stock options | 2,397 | 1,431 |
| Net increase (decrease) in borrowings | 209,000 | $(5,000)$ |
| Acquisitions | $(213,665)$ | $(60,527)$ |
| Repurchases of Tredegar common stock |  | $(34,163)$ |
| New venture capital investments, net of proceeds from disposals | $(29,648)$ | $(10,807)$ |
| Other, net | 126 | (357) |
| Net increase (decrease) in cash and cash equivalents | $(5,542)$ | $(93,492)$ |
| Cash and cash equivalents, end of period | \$ 19,867 | \$ 26,573 |

At June 30, 1999, we had total debt of $\$ 234$ million, including $\$ 214$ million borrowed on a floating-rate basis under our $\$ 275$ million revolving credit facility. We believe that our current debt level (which represents $41 \%$ of total capitalization and $1.7 x$ pro forma EBITDA for the 12 months ended June 30, 1999) is within investment-grade guidelines. We are reviewing loan-financing alternatives to restore the available balance under the credit facility, and we expect to maintain our floating-rate exposure under any new loan. On August 10, 1999, 30 -day rollover borrowings under the credit facility carried an interest rate of $5.5 \%$.

Tredegar has exposure to the volatility of interest rates, polyethylene and polypropylene resin prices, aluminum ingot and scrap prices, foreign currencies, emerging markets and technology stocks.

See Liquidity and Capital Resources on page 16 for information on debt and interest-rate exposure.

Changes in resin prices, and the timing of those changes, could have a significant impact on profit margins in Film Products; however, those changes are generally followed by a corresponding change in selling prices. Profit margins in Aluminum Extrusions are sensitive to fluctuations in aluminum ingot and scrap prices but are also generally followed by a corresponding change in selling prices; however, there is no assurance that higher ingot costs can be passed along to customers.

In the normal course of business, we enter into fixed-price forward sales contracts with certain customers for the sale of fixed quantities of aluminum extrusions at scheduled intervals. In order to hedge our exposure to aluminum price volatility under these fixed-price arrangements, which generally have a duration of not more than 12 months, we enter into a combination of forward purchase commitments and futures contracts to acquire aluminum, based on the scheduled deliveries.

We sell to customers in foreign markets through our foreign operations and through exports from U.S. plants. The percentage of consolidated pretax income earned by geographic area for the first six months of 1999 and 1998 are presented below:

> Percentage of Consolidated Pretax Income Earned by Geographic Area*

|  | Six Months Ended June 30 |  |
| :---: | :---: | :---: |
|  | 1999 | 1998 |
| United States | 58 \% | 66 \% |
| Canada | 17 | 9 |
| Europe | 9 | 12 |
| Latin America | 8 | 9 |
| Asia | 8 | 4 |
| Total | 100 \% | 100 \% |

* Based on consolidated pretax income from continuing operations excluding venture capital activities and unusual items.

We attempt to match the pricing and cost of our products in the same currency and generally view the volatility of foreign currencies and emerging markets, and the corresponding impact on earnings and cash flow, as part of the overall risk of operating in a global environment. Exports from the U.S. are generally denominated in U.S. dollars. Our foreign operations in emerging markets have agreements with certain customers that index the pricing of our
products to the U.S. dollar or the German mark and the euro. Our foreign currency exposure on income from foreign operations in Europe primarily relates to the German mark and the euro. We believe that our exposure to the Canadian dollar has been substantially neutralized by the U.S. dollar-based spread (the difference between selling prices and aluminum costs) generated from Canadian casting operations and exports from Canada to the U.S. The recent acquisition of Exxon Films will increase the proportion of our income earned in the U.S.

We have investments in private venture capital fund limited partnerships and early-stage technology companies, including the stock of privately-held companies and the restricted and unrestricted stock of companies that have recently registered shares in initial public offerings. Investments in non-public companies are illiquid and the investments in public companies are subject to the volatility of equity markets and technology stocks. See Note 3 on page 8 for more information.

Year 2000 Information Technology Issues

The century date compliance problem, which is commonly referred to as the "Year 2000" problem, will affect many computers and other electronic devices that are not programmed to properly recognize dates starting with January 1, 2000. This could result in system failures or miscalculations. The potential impact of such failures include, among others, an inability to secure raw materials, manufacture products, ship products and be paid for products on a timely basis.

Since 1996, we have been actively planning and responding to the Year 2000 problem. Year 2000 reviews have been and will continue to be made to our Executive Committee and senior management. Periodic reviews with the Board of Directors began in August 1998.

Our Year 2000 compliance efforts are focused on internal computer-based information systems, external electronic interfaces and communication equipment, shop floor machines and other manufacturing and research process control devices. Remediation of systems requiring changes was completed at the end of 1998, except for revisions to a small portion of certain software programs, the replacement of certain software for the four aluminum extrusion plants recently acquired in Canada, and computer systems related to the acquisition of Exxon Films discussed below. Remediation efforts for the exceptions have extended into 1999. Testing of systems began in mid-1998 and will continue through 1999. We do not believe contingency plans are necessary for internal systems at this time. We are also actively evaluating the Year 2000 capabilities of parties with whom we have key business relationships (suppliers, customers and banks, for example). Contingency plans will be developed for these relationships as needed. Work to fix the Year 2000 problem is being performed largely by internal personnel and we do not track those costs. The incremental costs associated with correcting the problem are not expected to have a material adverse effect on our operating results, financial condition or cash flows.

The computer systems for Exxon Films are not Year 2000 compliant. We are replacing non-compliant systems (including internal computer-based information systems, communications equipment and shop floor machines) and integrating the business into the enterprise-wide systems infrastructure of Tredegar Film Products. We expect to complete all remediation efforts related to Exxon Films by the end of 1999 at a cost of approximately $\$ 1.9$ million, most of which will be capitalized and amortized over the estimated useful life of related assets.

While we believe that we are taking the necessary steps to resolve our Year 2000 issues in a timely manner, there can be no assurance that there will be no Year 2000 problems. If any such problems occur, we will work to solve them as quickly as possible. At present, we do not expect that any such problems will have a material adverse effect on our businesses. The failure, however, of a major customer or supplier to be Year 2000-compliant could have a material adverse effect on our businesses.

## New Accounting Standards

The Financial Accounting Standards Board has issued a new standard affecting the accounting for derivative instruments and hedging activities. This standard is not expected to significantly change our operating results, financial condition or disclosures. The new standard will be adopted in the first quarter of 2001.
(c)

OTHER INFORMATION
Submission of Matters to a Vote of Security Holders.
Tredegar's Annual Meeting of Shareholders was held on May 20, 1999. The following sets forth the vote results with respect to each of the matters voted upon at the meeting:

Election of Directors

|  | No. of <br> Votes "For" | No. of Votes <br> "Withheld" |
| :--- | ---: | ---: |
| Nominee | $33,346,508$ | 518,902 |
| Phyllis Cothran | $33,402,715$ | 462,695 |
| Richard W. Goodrum | $33,333,371$ | 532,039 |
| Floyd D. Gottwald, Jr. |  |  |
| There were no broker non-votes with respect to the election of |  |  |
| directors. |  |  |
| Approval of Auditors |  |  |
| Approval of the designation of PricewaterhouseCoopers LLP as |  |  |
| the auditors for Tredegar for 1999: |  |  |

No. of Votes
"For"
$33,564,304$

No. of Votes
"Against"
242,668
No. of
Abstentions
58,438
There were $1,198,653$ broker non-votes with respect to the approval of auditors.

Approval of the Amended and Restated Incentive Plan

| No. of Votes | No. of Votes | No. of |
| :---: | :---: | :---: |
| "For" | "Against" | Abstentions |
| $30,608,860$ | $2,913,765$ | 342,785 |

There were $1,198,653$ broker non-votes with respect to the approval of the Amended and Restated Incentive Plan.

Approval of the amendment of the Articles of Incorporation to change Tredegar's name from "Tredegar Industries, Inc." to "Tredegar Corporation":

| No. of Votes | No. of Votes | No. of |
| :---: | :---: | :---: |
| "For" | "Against" | Abstentions |
| $33,693,659$ | 104,279 | 67,472 |

There were $1,198,653$ broker non-votes with respect to the approval of the change of the corporation's name.

Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibit No.

2 Asset Purchase Agreement, dated April 23, 1999, by and between Exxon Chemical Company, a division of Exxon Corporation, and Tredegar (filed as Exhibit 2 to Tredegar's Current Report on Form 8-K dated May 17, 1999, as amended, and incorporated herein by reference)

3 Articles of Amendment
4 Rights Agreement, dated as of June 30, 1999, by and between Tredegar and American Stock Trust \& Transfer Company, as Rights Agent (filed as Exhibit 99.1 to the Registration Statement on Form 8-A, as filed with the Securities and Exchange Commission on June 16, 1999, as amended, and incorporated herein by reference)

27 Financial Data Schedule
(b) Reports on Form 8-K.
o Registrant filed a Form 8-K dated May 17, 1999, with respect to:
o The acquisition of Exxon Films (see further information regarding this acquisition in Note 2 on page 5)
o The announcement of lower than expected results anticipated for 1999 due to a variety of factors affecting Film Products and operating losses expected at Therics (acquired April 8, 1999 - see Note 2 on page 5 for more information on Therics)
That Form 8-K was amended by Tredegar's filing of a Form 8-K/A on June 25, 1999, to include the historical and pro forma financial information relating to the acquisition of Exxon Films and other acquisitions.
0 Registrant filed a Form 8-K dated June 30, 1999, with regard to the approval by Tredegar's Board of Directors of a Rights Agreement effective June 30, 1999.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Tredegar Corporation
(Registrant)


## Exhibit No.

Description
Asset Purchase Agreement, dated April 23, 1999, by and between Exxon Chemical Company, a division of Exxon Corporation, and Tredegar (filed as Exhibit 2 to Tredegar's Current Report on Form 8-K dated May 17, 1999, as amended, and incorporated herein by reference)

Articles of Amendment
Rights Agreement, dated as of June 30, 1999, by and between Tredegar and American Stock Trust \& Transfer Company, as Rights Agent (filed as Exhibit 99.1 to the Registration Statement on Form 8-A, as filed with the Securities and Exchange Commission on June 16, 1999, as amended, and incorporated herein by reference)

Financial Data Schedule

THE SCHEDULE CONTAINS UNAUDITED SUMMARY FINANCIAL INFORMATION FOR TREDEGAR CORPORATION AND SUBSIDIARIES EXTRACTED FROM THE BALANCE SHEET FOR THE PERIOD ENDED MARCH 31, 1997 AND THE STATEMENT OF INCOME FOR THE THREE MONTHS ENDED JUNE 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.

|  | 1,000 |
| :---: | :---: |
|  | 6-MOS |
|  | DEC-31-1999 |
|  | JUN-30-1999 |
|  | 19,867 |
|  | 0 |
|  | 114,151 |
|  | 4,455 |
|  | 46, 090 |
|  | 187,431 |
|  | 452, 257 |
|  | 211,803 |
|  | 705,709 |
|  | 102,600 |
|  | 234, 000 |
|  | 0 |
|  | 0 |
|  | 98,290 |
|  | 239,305 |
| 705,709 |  |
|  | 374,381 |
|  | 373,363 |
|  | 294, 225 |
|  | 294, 225 |
|  | 37,215 |
|  | 654 |
|  | 1,806 |
|  | 39,463 |
|  | 13,975 |
|  | 25,488 |
|  | 0 |
|  | 0 |
|  | 0 |
|  | 25,488 |
|  | . 69 |
|  | . 65 |

